Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Acute Coronary Syndrome V: Nursing Management

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Coronary artery disease risk reclassification by a new acoustic-based score.

The international journal of cardiovascular imaging·2019

Same author

Influence of Cardiac CT based disease severity and clinical symptoms on the diagnostic performance of myocardial perfusion.

The international journal of cardiovascular imaging·2019

Same author

Diagnosing coronary artery disease after a positive coronary computed tomography angiography: the Dan-NICAD open label, parallel, head to head, randomized controlled diagnostic accuracy trial of cardiovascular magnetic resonance and myocardial perfusion scintigraphy.

European heart journal. Cardiovascular Imaging·2018

Same author

Chronic pain and the development of a symptom checklist: a pilot study.

Acta anaesthesiologica Scandinavica·2013

Same author

Left ventricular contractile function after distal protection in primary percutaneous coronary intervention: results from the Drug Elution and Distal Protection in ST-Elevation Myocardial Infarction trial.

International journal of cardiology·2009

Same author

Spontaneous coronary artery dissection: a Western Denmark Heart Registry study.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2009

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Late coronary stent thrombosis.

L Thuesen¹, N R Holm

¹Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark. leif.thuesen@ki.au.dk

|March 16, 2010

Summary

Coronary stent thrombosis, occurring early or late after percutaneous coronary intervention (PCI), is a serious concern. Late stent thrombosis (LST) is rare but severe, often linked to drug-eluting stents (DES).

Area of Science:

Cardiology
Biomaterials Science

Background:

Coronary stent thrombosis (ST) is a significant complication following percutaneous coronary intervention (PCI).
ST is categorized as early (within one month) or late (after one month), both posing risks of acute myocardial infarction and sudden cardiac death.
While early ST is associated with implantation factors and dual antiplatelet therapy, late ST (LST) is increasingly recognized, particularly after drug-eluting stent (DES) implantation.

Purpose of the Study:

To differentiate the pathogenetic mechanisms of early and late stent thromboses.
To explore the association between different types of DES and the risk of LST.
To investigate the potential role of polymer-based tissue reactions in very late stent thrombosis (VLST).

Main Methods:

Review of existing literature on coronary stent thrombosis.

Related Experiment Videos

Last Updated: Jun 15, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Analysis of pathogenetic mechanisms differentiating early, late, and very late stent thrombosis.

Evaluation of the impact of stent type (bare metal vs. drug-eluting) and polymer composition on thrombosis risk.

Main Results:

Early ST is primarily linked to PCI technique, lesion complexity, and dual antiplatelet therapy.
Late ST (LST) is rare but severe, predominantly observed with DES implantation.
Emerging evidence suggests VLST (occurring >1 year post-PCI) may be related to local tissue responses to stent polymers.

Conclusions:

Understanding the distinct mechanisms of early and late ST is crucial for risk stratification and management.
Newer generation DES with improved polymer formulations (tissue-friendly or bioabsorbable) hold promise for reducing LST risk.
Further research into polymer-tissue interactions is warranted to mitigate VLST.